Long‐term survival and loss in expectancy of life in a population‐based cohort of 7114 patients with diffuse large B‐cell lymphoma

Survival has improved among patients with diffuse large B‐cell lymphoma (DLBCL) with the addition of anti‐CD20 antibody therapy. We aimed to quantify trends and remaining loss in expectation of life (LEL) due to DLBCL at a national population‐based level. Patients diagnosed with DLBCL 2000‐2013 (N =...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2018-08, Vol.93 (8), p.1020-1028
Main Authors: Ekberg, Sara, Jerkeman, Mats, Andersson, Per‐Ola, Enblad, Gunilla, Wahlin, Björn E, Hasselblom, Sverker, Andersson, Therese M., Eloranta, Sandra, Smedby, Karin E.
Format: Article
Language:English
Subjects:
Antibodies
B-cell lymphoma
Cancer and Oncology
Cancer och onkologi
CD20 antigen
chemotherapy plus rituximab
chop
Clinical Medicine
Diagnosis
disease
flexible parametric models
Hematologi
Hematology
Immunotherapy
Klinisk medicin
Life span
Lymphocytes B
Lymphoma
Medical and Health Sciences
Medicin och hälsovetenskap
young-patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Survival has improved among patients with diffuse large B‐cell lymphoma (DLBCL) with the addition of anti‐CD20 antibody therapy. We aimed to quantify trends and remaining loss in expectation of life (LEL) due to DLBCL at a national population‐based level. Patients diagnosed with DLBCL 2000‐2013 (N = 7114) were identified through the Swedish Lymphoma Registry and classified according to the age‐adjusted International Prognostic Index (aaIPI). The novel measure LEL is the difference between remaining life years among patients and the general population and was predicted using flexible parametric models from diagnosis and among 2‐year survivors, by age and sex. Median age at DLBCL‐diagnosis was 70 (18‐105) years and 54.8% presented with stage III‐IV disease. On average, LEL due to DLBCL decreased from 8.0 (95% CI: 7.7‐8.3) to 4.6 (95% CI: 4.5‐4.6) years over the study period. By risk group, LEL was most reduced among patients with aaIPI ≥2 aged 50‐60 years. However, these patients were still estimated to lose >8 years in 2013 (eg, LELmales50years 8.6 years (95% CI: 5.0‐12.3)). Among 2‐year survivors, LEL was reduced from 6.1 years (95% CI: 5.6‐6.5) (aaIPI ≥ 2) and 3.8 years (95% CI: 3.6‐4.1) (aaIPI 
ISSN:0361-8609
1096-8652
1096-8652
DOI:10.1002/ajh.25147